Better Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Perry
- Full Time Employees
- 54
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 548 Market Street San Francisco CA United States of America 94104
- IPO Date
- Mar 17, 2021
- CIK
- 0001832415
- Website
- bettertx.com
- Similar Companies
- Business
- Better Therapeutics, Inc. (BTTX) develops prescription digital therapeutics that deliver cognitive behavioral therapy to treat the root causes of cardiometabolic diseases including type 2 diabetes, heart disease, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease; the company's platform features AspyreRx, the first FDA-authorized prescription digital therapeutic for adults with type 2 diabetes as an adjunct to standard care; its pipeline includes investigational candidates BT-002 for glycemic control in hypertension, BT-003 to reduce LDL cholesterol in hyperlipidemia, and BT-004 to improve liver health in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Better Therapeutics provides software-based solutions prescribed by physicians and accessed via mobile applications that deliver tailored lessons, skill-building modules, and goal-setting features to drive behavioral changes in eating and lifestyle patterns. The company, founded in 2015 and headquartered in San Francisco, California, operates primarily in the United States with a fully distributed workforce and approximately 54 employees. In recent developments, Better Therapeutics received FDA Breakthrough Device Designation for its digital therapeutic platform targeting advanced liver disease; the company strengthened its financial position through amendments to its debt facility with Hercules Capital and implemented significant cost reductions; it launched commercialization efforts for AspyreRx following FDA De Novo authorization in 2023 but faced challenges with market adoption and reimbursement, resulting in minimal revenues; in March 2024, Better Therapeutics filed for Chapter 11 bankruptcy protection, terminated employees, explored strategic alternatives including a potential sale of assets or wind-down, had its Nasdaq shares delisted, and transitioned trading to OTC markets; subsequently, Click Therapeutics acquired key assets including AspyreRx and development candidates BT-002, BT-003, and BT-004 to advance its pipeline in obesity, diabetes, hypertension, hyperlipidemia, and metabolic-associated steatohepatitis.
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)
Better Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual Conference
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes
Better Therapeutics, Inc. (BTTX) Q2 2023 Earnings Call Transcript